Glenmark Pharmaceuticals update on USFDA audit of Baddi unit
USFDA issues 7 observations through Form 48
Glenmark Pharmaceuticals announced that the Baddi unit of the Company underwent an USFDA audit from 06 November 2017 to 11 November 2017. The USFDA issued seven observations through the Form 48.Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content